Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADRIAMYCIN PFS vs IDAMYCIN PFS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.
Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.
Acute lymphoblastic leukemia,Acute myeloblastic leukemia,Wilms tumor,Neuroblastoma,Soft tissue and bone sarcomas,Breast cancer,Ovarian cancer,Transitional cell bladder cancer,Thyroid cancer,Gastric cancer,Hodgkin lymphoma,Non-Hodgkin lymphoma,Multiple myeloma,Small cell lung cancer
Treatment of acute myeloid leukemia (AML) in adults,Treatment of acute lymphocytic leukemia (ALL) (off-label)
60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).
12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).
Triphasic: initial α half-life 30 min (distribution), intermediate β half-life 3-4 hours (metabolism), terminal γ half-life 20-48 hours (prolonged due to extensive tissue binding and slow efflux from tissues).
Terminal elimination half-life of idarubicin is 20-30 hours; idarubicinol (active metabolite) has a terminal half-life of 45-60 hours, extending myelosuppression duration.
Primarily hepatic metabolism via aldo-keto reductases to doxorubicinol; also undergoes 4-O-demethylation and glucuronidation. CYP450 minimally involved.
Hepatic metabolism primarily via aldo-keto reductases to idarubicinol (active metabolite); further metabolism via glucuronidation.
Primarily hepatobiliary (∼50% as unchanged drug and metabolites in bile); renal excretion accounts for ∼5-12% over 72 hours; fecal elimination ~40%.
Renal (approximately 5-12% as unchanged drug and metabolites), biliary/fecal (significant, with 40-50% recovered in feces over 7 days).
∼70% bound to plasma proteins, primarily albumin; binding is concentration-dependent and saturable at high doses.
Idarubicin: 94-97% bound to plasma proteins (primarily albumin); idarubicinol: 90-95% bound.
Extensive: 20-30 L/kg (total body water far exceeded, indicating deep tissue compartment binding, especially in liver, spleen, heart, and bone marrow).
Vd: 40-90 L/kg (extensive tissue distribution, indicating high affinity for intracellular sites such as DNA).
Not bioavailable orally (0%, due to extensive first-pass metabolism and instability in GI tract); administered only intravenously.
Oral bioavailability: approximately 30% (limited clinical use; idarubicin is typically administered IV).
No specific dose adjustment recommended for renal impairment; however, monitor for toxicity. GFR < 10 m L/min: consider dose reduction by 50% due to potential accumulation of active metabolites.
GFR 20-50 m L/min: Administer 75% of dose; GFR <20 m L/min: Administer 50% of dose. Not dialyzable; no supplemental dose needed post-dialysis.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or reduce by 75% with extreme caution.
Child-Pugh Class B: Reduce dose by 25%; Child-Pugh Class C: Reduce dose by 50%. Severe hepatic dysfunction (bilirubin >3 mg/d L): Contraindicated unless benefit outweighs risk.
30-75 mg/m² IV every 21-28 days; cumulative dose limit 400-550 mg/m². Dose based on body surface area; for infants < 1 year or BSA < 0.5 m², use weight-based dosing: 1-2 mg/kg IV every 21 days.
Children: 12 mg/m² intravenously daily for 3 days (induction) or 12 mg/m² daily for 2 days (consolidation). For infants <0.5 m²: 0.75 mg/kg intravenously daily for 3 days.
No specific dose adjustment based on age alone; use with caution due to increased risk of cardiotoxicity and myelosuppression. Consider starting at lower end of dosing range (e.g., 45-60 mg/m² every 21 days) and monitor cardiac function.
No specific dose adjustment, but monitor for increased myelosuppression and cardiotoxicity. Consider dose reduction based on renal function and performance status.
Myocardial toxicity (including delayed congestive heart failure) may occur with cumulative doses >550 mg/m²; less if prior mediastinal irradiation. Extravasation causes severe tissue necrosis. Secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) reported. Hepatic impairment requires dose adjustment. Use during pregnancy only if benefit outweighs risk.
Severe myelosuppression when used at therapeutic doses; cardiac toxicity including potentially fatal congestive heart failure, acute left ventricular failure, and arrhythmias; secondary malignancies including acute myeloid leukemia and myelodysplastic syndrome; extravasation leading to severe tissue necrosis; reduce dose in patients with hepatic impairment.
Cardiotoxicity (cumulative dose-dependent, enhanced by prior chest irradiation, age >70, pre-existing cardiac disease); myelosuppression; extravasation injury; secondary malignancies; tumor lysis syndrome; hepatic impairment; radiation recall; mutagenic and carcinogenic potential; impairment of fertility.
Monitor cardiac function before and during therapy; cumulative dose increases risk of cardiotoxicity,Severe myelosuppression with risk of infection and bleeding,Extravasation risk: administer via secure IV line,Secondary malignancies reported,Hepatic and renal impairment may require dose adjustment,Tumor lysis syndrome,May impair fertility
Hypersensitivity to doxorubicin or any component; severe hepatic impairment; severe myelosuppression; baseline cardiac dysfunction; previous treatment with maximum cumulative doses of doxorubicin or other anthracyclines.
Hypersensitivity to idarubicin or other anthracyclines,Severe hepatic impairment (Child-Pugh class C),Severe renal impairment (creatinine clearance < 30 m L/min),Pre-existing severe myelosuppression not due to leukemia,Severe cardiac dysfunction (e.g., recent myocardial infarction, cardiomyopathy)
Grapefruit and grapefruit juice should be avoided as they may inhibit CYP3A4 metabolism and increase doxorubicin toxicity. No other significant food interactions; maintain adequate hydration and nutrition.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition affecting drug metabolism. No other significant food interactions.
FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal myelosuppression. Avoid use unless maternal benefit outweighs fetal risk.
Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first trimester, including malformations and spontaneous abortion. In the second and third trimesters, there is risk of fetal growth restriction, preterm labor, and neonatal myelosuppression. Use only if potential benefit justifies risk.
Not recommended. Doxorubicin is excreted into human breast milk; M/P ratio not available. Potential for serious adverse reactions in nursing infants (e.g., immunosuppression, neutropenia). Discontinue breastfeeding during treatment and for at least 10 days after last dose.
It is unknown if idarubicin is excreted in human breast milk. Due to potential for serious adverse reactions in nursing infants, including immunosuppression and carcinogenesis, breastfeeding is contraindicated during treatment and for at least 1 month after the last dose. M/P ratio is not established.
No established dose adjustments in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require monitoring for toxicity or efficacy. Use lowest effective dose; consider dose reduction for myelosuppression or cardiotoxicity. Administration frequency may be modified based on gestational age and maternal tolerance.
No specific dose adjustments have been established for pregnancy. Physiological changes in pregnancy (increased plasma volume, altered hepatic metabolism) may affect pharmacokinetics but no formal studies exist. Use standard dosing based on body surface area with caution and monitor for toxicity.
Pre-medicate with antiemetics (e.g., 5-HT3 antagonist) prior to administration. Monitor left ventricular ejection fraction (LVEF) at baseline and periodically due to cumulative dose-related cardiotoxicity (lifetime max 450-550 mg/m2, lower with prior chest radiation). Extravasation causes severe tissue necrosis; administer through a free-flowing IV line. Reduce dose in hepatic impairment (bilirubin >1.2 mg/d L). Observe for urine discoloration (red) for 1-2 days post-infusion. Avoid concurrent use with trastuzumab or other cardiotoxic agents.
Administer IV only; extravasation causes severe tissue necrosis. Premedicate with antiemetics. Monitor for cardiotoxicity with cumulative doses >550 mg/m2 (or 450 mg/m2 with prior chest irradiation). Urine may turn reddish for 1-2 days. Leukocyte nadir occurs 10-14 days after administration.
Doxorubicin may cause temporary reddish discoloration of urine for 1-2 days after treatment; this is harmless.,Report any signs of infection (fever, sore throat), unusual bleeding or bruising, mouth sores, or shortness of breath.,Your heart function will be checked before and during treatment; report any chest pain, palpitations, or swelling of ankles/feet.,This drug can cause nausea and vomiting; you will receive medications to prevent these symptoms.,Avoid pregnancy during treatment; use effective contraception. Doxorubicin can harm a fetus and may cause infertility.,Do not receive live vaccines during chemotherapy. Avoid contact with people who have recently received oral polio vaccine.,Take oral care measures (soft toothbrush, bland rinses) to prevent mouth sores.,Limit intake of grapefruit and grapefruit juice as they may affect the drug's metabolism.
This drug can cause severe nausea and vomiting; take antiemetics as prescribed.,Your urine may appear red or orange for 1-2 days after treatment; this is normal.,Report any pain, redness, or swelling at the injection site immediately.,Avoid receiving live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 6 months after therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADRIAMYCIN PFS vs IDAMYCIN PFS, answered by our medical review team.
ADRIAMYCIN PFS is a Anthracycline Antineoplastic that works by Intercalation between DNA base pairs, inhibition of topoisomerase II, and generation of free radicals leading to DNA damage and apoptosis.. IDAMYCIN PFS is a Anthracycline Antineoplastic that works by Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADRIAMYCIN PFS and IDAMYCIN PFS depend on the specific clinical indication. These are both Anthracycline Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADRIAMYCIN PFS is: 60-75 mg/m² IV every 21 days as a single agent; 40-60 mg/m² IV every 21-28 days in combination regimens. Cumulative lifetime dose not to exceed 450-550 mg/m² (or 400 mg/m² with prior chest irradiation).. The standard adult dose of IDAMYCIN PFS is: 12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADRIAMYCIN PFS and IDAMYCIN PFS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADRIAMYCIN PFS is classified as Category C. FDA Pregnancy Category D. First trimester: high risk of major congenital malformations (e.g., CNS, cardiovascular) and spontaneous abortion. Second and third trimesters: risk of fe. IDAMYCIN PFS is classified as Category C. Idarubicin is embryotoxic and teratogenic in animal studies. Human data are limited, but it is classified as FDA Pregnancy Category D. There is evidence of fetal risk in the first . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.